1186 Baseline Vitamin D Levels Do Not Influence SVR in Patients With Chronic HCV Genotype 1 or 4 Infection Undergoing Peginterferon/Ribavirin Treatment

Stauber, R.E.; Scherzer, Thomas–Matthias; Putz-Bankuti, Csilla; Matejka, J.; Spindelboeck, Walter; Zinober, Kerstin; Bernhardt, Stephan; Wehr, Elisabeth; Stojaković, Tatjana; Kessler, Hermann; Ferenci, Péter; Obermayer–Pietsch, Barbara

doi:10.1016/s0168-8278(11)61188-4

Cited by 6 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study is the smallest in the meta-analysis, with only 80 genotype 1 patients. With this study excluded from the meta-analysis, the findings strongly confirmed no relationship between the mean baseline 25 [22,23] that were eligible for, but not included in their meta-analysis. They evaluated a categorical 25(OH)D level of 30 ng/ml, rather than the more statistically robust continuous mean 25(OH)D level, and found that those with a 25(OH)D level >30 ng/ml had a higher chance of SVR (OR 1.57, 95% CI 1.…”

Section: Discussionmentioning

confidence: 55%

See 1 more Smart Citation

Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: A systematic review and meta-analysis

Kitson

Sarrazin

Toniutto

et al. 2014

Journal of Hepatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 55%

“…Therefore, 11 studies, comprised of 7 published articles [5][6][7][8][9][10][11] and 4 conference abstracts [20][21][22][23], involving 2605 patients with chronic HCV infection, were included in the meta-analysis (Fig. 1).…”

Section: Literature Searchmentioning

confidence: 99%

Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: A systematic review and meta-analysis

Kitson

Sarrazin

Toniutto

et al. 2014

Journal of Hepatology

View full text Add to dashboard Cite

“…There were 51 studies with a total of 11,102 HCV-4 patients included in the primary analysis (Table 1)[10–16, 18, 27, 28, 34, 35, 37–42, 45, 46, 48, 53–56, 59, 62, 63, 65–67, 69, 71–73, 75–81, 83–85, 88, 90, 91, 93, 95, 96]. The majority of studies (40/51, 78%) originated from the Middle East[10–13, 15, 16, 18, 27, 28, 34, 35, 37, 40–42, 45, 46, 53–56, 59, 62, 63, 66, 67, 69, 72, 75, 78, 80, 81, 83–85, 88, 91, 95] and Europe (9/51, 18%)[14, 38, 39, 65, 71, 76, 79, 93, 96].…”

Section: Resultsmentioning

confidence: 99%

“…The majority of studies (40/51, 78%) originated from the Middle East[10–13, 15, 16, 18, 27, 28, 34, 35, 37, 40–42, 45, 46, 53–56, 59, 62, 63, 66, 67, 69, 72, 75, 78, 80, 81, 83–85, 88, 91, 95] and Europe (9/51, 18%)[14, 38, 39, 65, 71, 76, 79, 93, 96]. One originated in Cameroon[77] and one multi-center study was conducted in 19 countries[73].…”

Section: Resultsmentioning

confidence: 99%

“…When comparing RCTs versus non-RCT studies, we observed a pooled SVR rate of 60% (CI: 53–68%) in the six RCTs[10, 13, 16, 18, 54, 93] compared to 52% (CI: 49–55%) in 45 non-RCTs[11, 12, 14, 15, 27, 28, 34, 35, 37–42, 45, 46, 48, 53, 55, 56, 59, 62, 63, 65–67, 69, 71–73, 75–81, 83–85, 88, 90, 91, 95, 96] (Figure 3). This finding was statistically significant with p =0.043.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Meta-analysis

Yee

Nguyen

Zhang

et al. 2014

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Background The burden of hepatitis C virus genotype 4 (HCV-4) is high in Africa and East Mediterranean countries. Previous reports estimate sustained virologic response (SVR) rates in HCV-4 to be ~20–70%. However, many of these studies are limited by different study designs and small sample sizes. Aim Our aim was to evaluate treatment outcome and host/viral factors on SVR in HCV-4 patients treated with pegylated interferon and ribavirin (PEG IFN+RBV) in a systematic and quantitative fashion. Methods A comprehensive literature search in MEDLINE and EMBASE for ‘genotype 4’ was conducted in November 2013. Abstracts from AASLD, APASL, DDW, and EASL in 2012/2013 were reviewed. Inclusion criteria were original studies with ≥25 treatment-naïve HCV-4 patients treated with PEG IFN+RBV. Exclusion criteria were co-infection with HIV, HBV, or other genotypes. Effect sizes were calculated using random-effects models. Heterogeneity was determined by Cochrane Q-test (p-value <0.05) and I-squared statistic (>50%). Results We included 51 studies (11,102 HCV-4 patients) in the primary analysis. Pooled SVR was 53% (95% CI: 50–55%) (Q-statistic = 269.20, p<0.05; I2 = 81.43). On sub-group analyses, SVR was significantly associated with lower viral load, OR 3.05 (CI 1.80–5.17, p<0.001); mild fibrosis, OR 3.17 (CI 2.19–4.59, p<0.001); and favorable IL28B polymorphisms, rs12979860 CC versus CT/TT, OR 4.70 (CI 2.87–7.69, p<0.001), and rs8099917 TT versus GT/GG, OR 5.21 (CI 2.31–11.73, p<0.001). Conclusions HCV-4 patients treated with PEG IFN+RBV may expect SVR rate of ~50%. Lower viral load, mild fibrosis, and favorable IL28B (rs12979860 CC and rs8099917 TT) are positively associated with SVR.

show abstract

The association between serological and dietary vitamin D levels and hepatitis C‐related liver disease risk differs in African American and white males

White

Tavakoli–Tabasi

Kanwal

et al. 2013

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background Vitamin D may affect the severity of HCV-related liver disease. We examined the association between serum vitamin D levels and advanced liver disease in a multiethnic U.S. cohort of HCV patients, and accounted for dietary and supplemental intake. Methods We measured serum 25-hydroxyvitamin D levels and FibroSURE-ActiTest to assess hepatic pathology in a cohort of HCV-infected male veterans. We estimated and adjusted for daily intake of vitamin D from diet using a Dietary History Questionnaire, and dispensed prescriptions prior to study enrollment. We used race-stratified logistic regression analyses to evaluate the relationship between serum vitamin D levels and risk of advanced fibrosis (F3/F4-F4) and advanced inflammation (A2/A3-A3). Results A total of 163 African American (AA) and 126 White non-Hispanics were studied. Overall, ~44% of AAs and 15% of Whites were vitamin D deficient or insufficient (<20 ng/mL); 4% of AAs and 9% of Whites had an elevated level (>50 ng/mL). Among AAs, patients with elevated serum vitamin D levels had significantly higher odds of advanced fibrosis (OR=12.91, p=0.03) than those with normal levels. In contrast, AAs with insufficient or deficient levels had > two-fold excess risk of advanced inflammation (p=0.06). Among Whites, there was no association between vitamin D levels and advanced fibrosis (F3/F4-F4) or inflammation (A2/A3-A3) risk. Conclusions We observed potential differences in the association between vitamin D levels and degree of HCV-related hepatic fibrosis between White and AA males. Additional research is necessary to confirm that high serum vitamin D levels may be associated with advanced fibrosis risk in African American males, and to evaluate racial differences exist in HCV-infected females.

show abstract

1186 Baseline Vitamin D Levels Do Not Influence SVR in Patients With Chronic HCV Genotype 1 or 4 Infection Undergoing Peginterferon/Ribavirin Treatment

Cited by 6 publications

References 0 publications

Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: A systematic review and meta-analysis

Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: A systematic review and meta-analysis

Meta-analysis

The association between serological and dietary vitamin D levels and hepatitis C‐related liver disease risk differs in African American and white males

Contact Info

Product

Resources

About